The Coronary Artery Revascularisation in Diabetes (CARDia) trial is an investigator-initiated study and is the first prospective study designed specifically to address the hypothesis that optimal percutaneous coronary intervention (PCI) with stenting and abciximab is not inferior to up-to-date coronary artery bypass grafting (CABG) as a revascularisation strategy for diabetics with multivessel or complex single vessel coronary disease.
Why do we need the CARDia trial?
May 2003Br J Cardiol (Acute Interv Cardiol) 2003;10:AIC 37–AIC 40 Leave a commentClick any image to enlarge
